Aggarwal Neelum T, Shah Raj C, Bennett David A
Department of Neurology, Rush Alzheimer's Disease Center & Family Medicine at Rush University Medical Center, Chicago, USA.
Indian J Med Res. 2015 Oct;142(4):369-82. doi: 10.4103/0971-5916.169193.
Alzheimer's disease (AD) is a progressive and irreversible neurodegenerative disease. In humans, AD becomes symptomatic only after brain changes occur over years or decades. Three contiguous phases of AD have been proposed: (i) the AD pathophysiologic process, (ii) mild cognitive impairment due to AD, and (iii) AD dementia. Intensive research continues around the world on unique diagnostic markers and interventions associated with each phase of AD. In this review, we summarize the available evidence and new therapeutic approaches that target both amyloid and tau pathology in AD and discuss the biomarkers and pharmaceutical interventions available and in development for each AD phase.
阿尔茨海默病(AD)是一种进行性且不可逆的神经退行性疾病。在人类中,AD只有在大脑经过数年或数十年发生变化后才会出现症状。AD已被提出有三个连续阶段:(i)AD病理生理过程,(ii)由AD导致的轻度认知障碍,以及(iii)AD痴呆。世界各地围绕与AD每个阶段相关的独特诊断标志物和干预措施仍在持续深入研究。在本综述中,我们总结了现有的证据以及针对AD中淀粉样蛋白和tau病理的新治疗方法,并讨论了AD每个阶段可用的和正在研发的生物标志物及药物干预措施。